CG Oncology Raises $380 Million in Nasdaq IPO Priced Above Range
4.9 (792) · € 23.00 · En Stock
Bladder cancer biotech CG Oncology raises $380 million in IPO
CG Oncology Goes Public @$19 per Share, Targeting $10B Bladder Cancer Market—Lots of Risks
CG Oncology Is Late Stage Looker For Life Science Investors (Pending:CGON)
Nasdaq Unveils New MarketSite IPO Floor Ahead of Arm, Instacart Debuts - Bloomberg
Biotech CG Oncology Soars 96% in Debut After Expanded IPO - Bloomberg
Fractyl Health sets terms of IPO; Could be 1st in Mass. in 2024 - Boston Business Journal
Kyle LaHucik on LinkedIn: Fractyl Health files for IPO to back obesity gene therapy, seeking to…
CG Oncology IPO Soars 96% on Day 1 - Orange County Business Journal
Celebrating Listings & Milestone Moments at Nasdaq in 2023
